Cellectis has filed a patent for a method of adaptive cell immunotherapy that aims to reduce translocations and cell deaths during genetic modification of primary immune cells. The invention allows for the creation of safer immune cells with multiple genetic modifications, such as triple or quadruple gene inactivation, for use in therapeutic treatments. One claim of the patent is for an mRNA molecule encoding a PD-1-targeting TALEN with specific amino acid sequences. GlobalData’s report on Cellectis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cellectis, CAR-T cell based therapies was a key innovation area identified from patents. Cellectis's grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for an mrna molecule encoding a pd-1-targeting talen
A recently filed patent (Publication Number: US20230287454A1) describes mRNA molecules and gene-edited primary immune cells for targeting PD-1, a protein involved in immune regulation. The patent claims an mRNA molecule encoding a PD-1-targeting TALEN (Transcription Activator-Like Effector Nuclease) with specific amino acid sequences. These sequences, identified as SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 9, are believed to be effective in targeting PD-1.
The patent also claims a population of gene-edited primary immune cells produced by transiently expressing a PD-1-targeting TALEN in the cells. This is achieved by introducing a rare-cutting sequence-specific endonuclease reagent, which acts as the PD-1-targeting TALEN, into the primary immune cells. The endonuclease reagent is designed to have the same amino acid sequences as mentioned earlier (SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 9).
Furthermore, the patent claims that the gene-edited primary immune cells can be T cells, NK cells, or immune cells obtained from a tumor, such as tumor infiltrating lymphocytes (TILs). This suggests that the technology described in the patent can be applied to various types of immune cells and potentially used in cancer immunotherapy.
In summary, the patent describes mRNA molecules encoding PD-1-targeting TALENs and gene-edited primary immune cells produced using these molecules. The technology aims to target PD-1, a protein involved in immune regulation, and can be applied to different types of immune cells. This patent may have implications for the development of novel therapies in the field of cancer immunotherapy.
To know more about GlobalData’s detailed insights on Cellectis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
